CA3139285A1 — Casein kinase 1e inhibitor, pharmaceutical composition and application thereof
Assigned to Hangzhou Healzen Therapeutics Co Ltd · Expires 2020-12-30 · 5y expired
What this patent protects
Disclosed in the present invention is a novel substituted pyrazolopyrimidine compound that inhibits the activity of casein kinase 1? (CK1?) and a stereoisomer or stereoisomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and an application thereof in …
USPTO Abstract
Disclosed in the present invention is a novel substituted pyrazolopyrimidine compound that inhibits the activity of casein kinase 1? (CK1?) and a stereoisomer or stereoisomer mixture thereof, or a pharmaceutically acceptable salt or solvate thereof, and an application thereof in preparation of drugs for treating diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1? (CK1?). The compound of the present invention has an inhibitory activity on CK1? kinase, OCI-LY10 cells and Karpas299 cells, shows good anti-tumor activity in an OCI-LY10 subcutaneous xenogeneic model and shows excellent synergistic anti-tumor activity in combination with BTK inhibitors. The compound of the present invention has good pharmacokinetics properties and may be used alone or in combination with other drugs to treat diseases, disorders or conditions that benefit from the inhibition of the activity of the casein kinase 1?, the diseases, disorders or conditions comprising tumors, autoimmune diseases, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.